Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANIQOL: Digital monitoring of symptoms in cabozantinib + nivolumab for advanced clear-cell renal carcinoma
2024-518991-30-00Phase 4Authorised
- Sponsor
- Centre François Baclesse
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cabozantinib and nivolumab in clear cell renal cell carcinoma (ccRCC), sponsored by Centre François Baclesse. Planned start Jun 2025; status: authorised.
02
Drugs
cabozantinibnivolumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2024-518991-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518991-30-00.